The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data.
Jessica A. Zerillo
No relevant relationships to disclose
Trang Pham
No relevant relationships to disclose
Pamela Kadlubek
No relevant relationships to disclose
Jane Alcyne Severson
No relevant relationships to disclose
Emily Mackler
No relevant relationships to disclose
Joseph O Jacobson
No relevant relationships to disclose
Douglas W Blayney
Employment or Leadership Position - Stanford University School of Medicine, Stanford Cancer Institute
Consultant or Advisory Role - PRM Pharmaceutical; UnitedHealthcare
Stock Ownership - Google; IBM; Oracle; UnitedHealth Group
Honoraria - ASCO; Cancer Centers of Excellence; McClaren Cancer Institute; Michigan Oncology Consortium
Research Funding - National Cancer Institute
Other Remuneration - ASCO; Michigan Oncology Quality Consortium